Use Of Fragmin In Hemodialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Chronic Renal Failure
Interventions
DRUG

Fragmin

variable dosing regimen

Trial Locations (19)

T5G 0B8

Royal Alexandra Hospital, Edmonton

T6G 2B7

University of Alberta Hospital, Edmonton

T6L 5X8

Grey Nuns Community Hospital, Edmonton

E2L 4L2

Horizon Health Network/Saint John Regional Hospital, Saint John

A1B 3V6

Eastern Regional Health Authority, Health Sciences Centre, St. John's

A1C 5B8

Eastern Regional Health Authority, St. Clare's Mercy Hospital, St. John's

A1E 4J8

Eastern Regional Health Authority, Waterford Hospital, St. John's

B3H 2Y9

Queen Elizabeth II Health Sciences Center (QEII) - VG Site, Halifax

L6R 3J7

William Osler Health System - Bramptom Civic Hospital, Brampton

N6A 5A5

London Health Sciences Centre, University Hospital, London

N6K 1M6

London Health Sciences Centre, Kidney Care Centre, London

L9W 4X9

William Osler Health System, Orangeville

J4V 2H1

Centre intégré de santé et de services sociaux de la Montérégie-Centre, Greenfield Park

J4V 3M3

Centre externe de néphrologie CISSS de la Montérégie-Centre, Greenfield Park

H2X 3J4

Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Saint-Luc, Montreal

H3M 3E3

CIUSSS du Nord-de-l'Ile-de-Montreal, Montreal

H4J 1C5

CIUSSS du Nord-de-l'Ile-de-Montreal, Montreal

G1R 2J6

CHU de Quebec (Pavillon Hotel-Dieu de Quebec), Québec

J4R 2L1

Centre externe de néphrologie CISSS de la Montérégie-Centre, Saint-Lambert

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01879618 - Use Of Fragmin In Hemodialysis | Biotech Hunter | Biotech Hunter